It is focused on developing novel and highly disease-specific immunotherapies for autoimmune diseases, cancer and chronic infections.

The approach of the company, which spins out from the recognized group of Professor Inger Sandlie, University of Oslo, involves targeting receptors at initiation of the immunological cascade.